Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Part 1: Causes of treatment variability
- Pharmacological treatment in psychiatry
- Genetic, environmental & clinical factors
- Biological interactions
- Part 2: metabolic enzyme genetic variants
- Drug metabolism
- CYP common mutations
- Main metabolic pathways
- CYP polymorphisms and plasma concentrations
- Starting dose for CYP2D6 metabolised drugs
- CYP polymorphisms and level of efficacy
- CYP Meta-analysis
- Part 3: genetic influence on treatment response
- Pharmacological profile of psychotropics
- D2 occupancy and drug response
- Dopamine receptors
- Dopamine genetic variants and treatment efficacy
- 5-HT2A receptor
- 5-HT2A meta analyses
- 5-HTT (SLC6A4)
- Meta-analyses in Caucasians (SSRIs)
- Gene and environment interactions
- Serotonin genetic variants and treatment
- Other receptor variants and treatment outcome
- Pharmacogenetic associations with efficacy
- Part 4: genetic influence on treatment side effects
- Treatment-induced adverse reactions
- Treatment-induced weight gain
- Genes implicated in weight gain
- Regulation of energy intake and expenditure
- Genetic alterations with movement disorders
- 5-HTT and antidepressant induced mania
- Dopamine genetic variants and side effects
- Serotonin genetic variants and side effects
- Pharmacogenetic associations with side effects
- Part 5: prediction tests for drug response
- Genetic prediction of treatment response
- Available pharmacogenetic tests in psychiatry
- Conclusion
- References (1)
- References (2)
- References (3)
Topics Covered
- Pharmacological treatment in psychiatry
- Causes of treatment variability
- Contribution of genetic variants of the CYP enzymes to drug metabolism
- Influence of genetic variance on drug treatment
- Influence of genetic variance on treatment-induced side-effects
- Prediction tests for psychotropic drug response
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Arranz, M. (2014, December 2). Tailoring psychiatric treatment using genetic information: pharmacogenetic prediction of treatment response [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 5, 2024, from https://doi.org/10.69645/LAUY2727.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Maria Arranz has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Tailoring psychiatric treatment using genetic information: pharmacogenetic prediction of treatment response
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
The
content of this talk
will focus on the pharmacogenetic
prediction of treatment response
in psychiatry and will
include information
on the most significant
findings in the area
and their clinical applications.
0:14
The talk will be divided
into five chapters.
The first part will deal with the
causes of treatment variability.
The second part will explain the
contribution of genetic variance
in the metabolic enzymes
to treatment variability.
The third part will summarize
genetic findings related
to treatment response, followed by
a summary of genetic factors related
to side effects induced
by psychotropic drugs.
And finally, we will talk
about existing genetic tests
and their application for
the prediction of response
to psychotropic drugs.
0:48
We will start by talking on the
causes of treatment variability.
0:53
The mainstay treatment of
severe mental disorders
such as schizophrenia
and bipolar disorder
is the use of psychotropic drugs.
However, not all patients
respond to treatment.
30% to 50% of treated
patients fail to respond.
And about 60% to 70% percent
develop long-lasting and severe side
effects, which can be
become life threatening.
These side effects include
extrapyramidal side effects, weight
gain and other phenotypes
contributing to metabolic syndrome,
sexual dysfunction,
and suicidal ideation.
Psychotropic drugs have a
complex pharmacological profile.
They target a variety of
neurotransmitter systems.
However, it is not
clear which targets
are important for the
therapeutic action,
and the mechanism of action of
psychotropic drops remains unclear.
Pharmacogenetic studies try to
identify genetic variance that
influence treatment
response and contribute
to the development of side effects.
The identification of
response-related variance
will help to discern targets
of therapeutic value.
This information might help to
predict treatment response based
on the genetic predisposition
of the patient.
Hide